ACC 22: Findings from the ADAPT-TAVR Trial | Dr Duk-Woo Park

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

In this short interview, Dr Duk-Woo Park (Asan Medical Center, Seoul, KR) discusses the findings from the ADAPT-TAVR Randomized Clinical Trial. The trial investigated Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR. Presented first at ACC.22, ADAPT-TAVR shows that the overall incidence of leaflet thrombosis on CT scans was less frequent (8.5% difference; risk ratio of 0.53) with the edoxaban therapy than with the DAPT therapy, although it did not reach statistical significance.

Discussion Points
-Rationale of the Trial
-Study Design, Endpoints and Patient Population
- Key Results
-Impact on Research and Practice
-Take-home Messages

Recorded remotely from Seoul, April 2022.
Editor: Mirjam Boros

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.